Taurine lends hand to repair cells damaged in multiple sclerosis

December 8, 2017, The Scripps Research Institute
Demyelination by MS. The CD68 colored tissue shows several macrophages in the area of the lesion. Original scale 1:100. Credit: Marvin 101/Wikipedia

New research suggests that administering taurine, a molecule naturally produced by human cells, could boost the effectiveness of current multiple sclerosis (MS) therapies. Scientists at The Scripps Research Institute (TSRI) found that taurine helps spark a process called remyelination, which is crucial to repairing the nerve cells damaged in multiple sclerosis.

"Remission of MS symptoms is dependent on the process of remyelination, so using taurine in combination with an existing MS drug and a future remyelination-inducing treatment may help patients by improving overall efficacy," says Luke Lairson, PhD, assistant professor of chemistry at TSRI and co-senior author of the study. "This could be something to add to an MS therapeutic regime."

The discovery also highlights the potential for a technique called "metabolomic profiling," which can identify useful endogenous metabolites the body already makes in small quantities, such as taurine, for new applications in drug therapies.

"Metabolomic profiling can offer unique insight into many different diseases, both mechanistically and therapeutically," says study co-senior author Gary Siuzdak, PhD, senior director of TSRI's Scripps Center for Metabolomics and professor of chemistry, molecular and computational biology.

The research was published recently in the journal Nature Chemical Biology.

Taurine helps drive cell maturation

Multiple sclerosis is an autoimmune disease that develops when the body begins attacking the protective myelin sheaths on nerve . Without healthy myelin sheaths, cannot communicate properly, and patients experience symptoms such as numbness, difficulty walking, slurred speech and vision loss.

Although there is no cure for MS, some current drug therapies can reduce MS relapses by encouraging re-myelination. In a 2013 Nature study, Lairson and colleagues showed that the drug benztropine, approved for Parkinson's disease, may also help MS patients by inducing cells called oligodendrocyte precursor cells to mature into myelin-producing oligodendrocytes and repair damaged nerves.

Lairson's next step was to find molecules that could make remyelination-inducing drugs even more effective, so he teamed up with Siuzdak to test the potential of molecules called endogenous metabolites to influence oligodendrocyte precursor cells. Endogenous (meaning "originating from within") metabolites are molecules naturally made by cells and include sugars, fatty acids and amino acids.

The new analysis and follow-up tests in cells showed that while the endogenous metabolite taurine cannot induce oligodendrocyte precursor cell maturation on its own, it can lend a helping hand when combined with the drugs benztropine or miconazole. The researchers described taurine as a "feedstock."

"Combining taurine with drugs that induce differentiation significantly enhances the process," says Lairson. "You get more myelin."

Lairson says this discovery is exciting because has already been shown to be safe at certain doses and is readily used by the brain. "We still need to do tests in rodent models, but this is a good starting point," he said.

Advances at TSRI have big implications for medicine

With this study's finding that administering a particular endogenous can influence a cell's fate and function, researchers have a new path for developing novel therapies for many diseases.

Metabolomic profiling takes advantage of technical developments, led by Siuzdak at TSRI, which scientists can use to analyze metabolic perturbations in disease and then apply that information to decipher mechanistic details. Ultimately, researchers hope to identify active endogenous metabolites with potential to reverse pathology-related phenotypes.

Siuzdak is encouraged by the nearly 21,000 scientists who currently use his lab's cloud-based XCMS/METLIN metabolomic profiling platform for these types of studies—and the interesting active roles metabolites are exhibiting.

"Unlike other omic technologies, the beauty of metabolomics and activity testing is that metabolites are readily commercially accessible, generally inexpensive, and can directly impact phenotype quickly," says Siuzdak. "We are no longer passive observers but instead active participants."

Explore further: Elucidation of the molecular mechanisms involved in remyelination

More information: Brittney A Beyer et al, Metabolomics-based discovery of a metabolite that enhances oligodendrocyte maturation, Nature Chemical Biology (2017). DOI: 10.1038/nchembio.2517

Related Stories

Elucidation of the molecular mechanisms involved in remyelination

September 3, 2015
Researchers in Japan have revealed the molecular mechanism involved in the process of repair to damage of the myelin sheath.

Protamine neutralizes CSPG-mediated inhibition of oligodendrocyte differentiation

December 8, 2017
Remyelination is a critical repair process in demyelinating diseases such as multiple sclerosis (MS). Chondroitin sulfate proteoglycans (CSPGs), a family of large molecules consisting of a core protein and glycosaminoglycans ...

New strategy to treat multiple sclerosis shows promise in mice

October 9, 2013
Scientists at The Scripps Research Institute (TSRI) have identified a set of compounds that may be used to treat multiple sclerosis (MS) in a new way. Unlike existing MS therapies that suppress the immune system, the compounds ...

New study shows taurine supplements may improve performance recovery

November 13, 2017
New research recently published in the Antioxidants journal, suggests taurine supplementation taken after exercise, may help improve the rate of muscle recovery.

New clues to myelination could help identify ways to intervene in neurodegenerative diseases

December 8, 2016
Researchers at the University at Buffalo have identified a critical step in myelination after birth that has significance for treating neurodegenerative diseases like multiple sclerosis, in which myelin is lost or damaged. ...

Recommended for you

New technique helps uncover changes in ALS neurons

June 22, 2018
Northwestern Medicine scientists have discovered that some neurons affected by amyotrophic lateral sclerosis (ALS) display hypo-excitability, using a new method to measure electrical activity in cells, according to a study ...

Broken shuttle may interfere with learning in major brain disorders

June 22, 2018
Unable to carry signals based on sights and sounds to the genes that record memories, a broken shuttle protein may hinder learning in patients with intellectual disability, schizophrenia, and autism.

Watching stem cells repair spinal cord in real time

June 22, 2018
Monash University researchers have restored movement and regenerated nerves using stem cells in zebra fish where the spinal cord is severely damaged.

Scientists discover fundamental rule of brain plasticity

June 21, 2018
Our brains are famously flexible, or "plastic," because neurons can do new things by forging new or stronger connections with other neurons. But if some connections strengthen, neuroscientists have reasoned, neurons must ...

Waking up is hard to do: Prefrontal cortex implicated in consciousness

June 21, 2018
Philosophers have pondered the nature of consciousness for thousands of years. In the 21st century, the debate over how the brain gives rise to our everyday experience continues to puzzle scientists. To help, researchers ...

Researchers find mechanism behind choosing alcohol over healthy rewards

June 21, 2018
A new study links molecular changes in the brain to behaviours that are central in addiction, such as choosing a drug over alternative rewards. The researchers have developed a method in which rats learn to get an alcohol ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.